New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 22, 2014
08:41 EDTHEBHemispherx analysis of new data on protection from pulmonary damage by H5N1
Hemispherx Biopharma announced that Dr. William M. Mitchell of Vanderbilt University presented a research paper on January 21 at the Keystone Symposia Conference on Pathogenesis of Respiratory Viruses entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus, or H5N1, by Low Dose Natural Human IFN- Administered to the Buccal Mucosa." The global threat of an influenza pandemic emerging from avian H5N1 and H7N9 influenza viruses that are highly pathogenic for humans has mobilized a variety of efforts to mitigate the potential devastating human and economic consequences. The study demonstrated a dose-dependent sparing of the H5N1 induced pulmonary damage. Clinical studies will be required to validate similar results in humans from highly pathogenic H5N1, H7N9, or similar emerging avian influenza viruses. Thus, both H5N1 influenza virus (the subject of collaboration with the Osterhaus group) and H7N9 influenza virus (the subject of ongoing collaboration with Prof. J. Richt's group at the Center of Excellence for Emerging and Zoonotic Animal Diseases, Kansas State University are susceptible to Alferon N treatment in various model systems. The latter work was conducted at research facilities designed to enhance the capability of the US Department of Homeland Security.
News For HEB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
09:20 EDTHEBOn The Fly: Pre-market Movers
Subscribe for More Information
September 30, 2014
18:36 EDTHEBOn The Fly: After Hours Movers
Subscribe for More Information
17:58 EDTHEBCDC confirms first U.S. patient diagnosed with Ebola virus
Subscribe for More Information
17:57 EDTHEBHemispherx up 12% after hours following CDC confirmation of Ebola case in U.S.
September 29, 2014
08:35 EDTHEBHemispherx expands research on potential Ebola treatments
Hemispherx Biopharma announced a widened set of research collaborations designed to develop therapeutic cocktails against Ebola which may potentially overcome the emergence of drug resistance due to Ebola virus mutation. The rapid acquisition of Ebola virus, or EBOV, sequence variation has been recently demonstrated during genomic surveillance of the current Ebola virus disease, or EVD. This observed genomic sequence variation suggests drugs that target specific viral non-variant protein sequences are at risk of mutation mediated activity failure. This complicates significantly the development of EBOV inhibitors in the drug development pipeline, some of which have been highly effective in treating advanced EVD in non-human primates. The two platform drugs of Hemispherx, Alferon N and Ampligen, have certain unique structural attributes and developmental histories which suggest potential incremental value with respect to inclusion in various Ebola therapeutic cocktails under development. First, both drugs have mechanisms of action, which are multifaceted by working thru cellular "molecular cascades" rather than target viral targets whose specificity is vulnerable to mutational change.
September 22, 2014
08:49 EDTHEBHemispherx announces Alferon LDO primate research peer-reviewed publication
Hemispherx Biopharma announced a peer-reviewed publication entitled "Protection from Pulmonary Tissue Damage Associated with Infection of Cynomolgus Macaques by Highly Pathogenic Avian Influenza Virus by Low Dose Natural Human IFN- Administered to the Buccal Mucosa" in the current issue of Antiviral Research 2014. This publication is a collaborative project conducted at Viroclinics Biosciences BV, Rotterdam, an internationally recognized research facility for the study of influenza viruses. The biohazard laboratories are directed by Prof. Albert D. M. E. Osterhaus, an internationally known virologist specializing in the study of pandemic influenza. Highly pathogenic avian influenza A virus is endemic in wild birds in Asia and the Middle East, causing disease and transmissibility in domestic poultry. Infection of humans with H5N1 is associated with a high mortality rate due to an alveolar destructive primary viral pneumonia frequently expressed clinically as acute respiratory distress syndrome.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use